IL21R hypomethylation as a biomarker for distinguishing benign and malignant breast tumours

Zishan Zanga Department of Epidemiology, School of Public Health, Nanjing Medical University, Nanjing, ChinaView further author information

Yifei Yinb Department of Thyroid and Breast Surgery, The Affiliated Huai’an Hospital of Xuzhou Medical University and The Second People’s Hospital of Huai’an, Huaian, ChinaView further author information

Chunlan Liua Department of Epidemiology, School of Public Health, Nanjing Medical University, Nanjing, ChinaView further author information

Qiang Zhua Department of Epidemiology, School of Public Health, Nanjing Medical University, Nanjing, ChinaView further author information

Xuandong Huangb Department of Thyroid and Breast Surgery, The Affiliated Huai’an Hospital of Xuzhou Medical University and The Second People’s Hospital of Huai’an, Huaian, ChinaView further author information

Hong Lic Department of Pathology, The Affiliated Huai’an Hospital of Xuzhou Medical University and The Second People’s Hospital of Huai’an, Huaian, ChinaCorrespondence[email protected]
View further author information

Rongxi Yanga Department of Epidemiology, School of Public Health, Nanjing Medical University, Nanjing, ChinaCorrespondence[email protected]

https://orcid.org/0000-0002-6655-1986 View further author information

show all

IL21R hypomethylation as a biomarker for distinguishing benign and malignant breast tumours

-) Clean supplemantary materials.docx

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

IL21R hypomethylation as a biomarker for distinguishing benign and malignant breast tumours

-) Clean supplemantary materials.docx

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date